Clinical Trial Update: A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 [Phase 3]

View source ↗

Summary

Pfizer is conducting a 104-week Phase 3 study of Ritlecitinib oral capsules in adults with nonsegmental vitiligo (stable and active). The trial status is ACTIVE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Pfizer | Conditions: Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | Phase 3 | Status: ACTIVE_NOT_RECRUITING